Understanding how tumors respond to radiation therapy
Shared Resource Core 1: Molecular Data Science and Advanced Dosimetry
This study is looking at how certain childhood tumors, like diffuse midline gliomas and neuroblastoma, respond to radiation therapy, using advanced technology to find out why some tumors resist treatment, with the goal of improving care for kids facing these tough cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10931445 on NIH RePORTER |
What this research studies
This research investigates the response of pediatric tumors, specifically diffuse midline gliomas and neuroblastoma, to radiation therapy by analyzing the molecular data and tumor microenvironment. It utilizes advanced data science and artificial intelligence to identify factors that contribute to tumor resistance and response to treatment. The project aims to create a comprehensive data hub for managing and analyzing molecular data, which will help in understanding the complexities of tumor behavior during radiotherapy. By integrating various data types, the research seeks to improve treatment strategies for these challenging cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with diffuse midline gliomas or neuroblastoma who are undergoing or considering radiation therapy.
Not a fit: Patients with other types of cancers or those not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective radiation therapies for pediatric cancers, improving survival rates and quality of life for young patients.
How similar studies have performed: Previous research has shown promise in using data science and AI to enhance cancer treatment strategies, indicating that this approach could yield significant advancements.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Michor, Franziska — Dana-Farber Cancer Inst
- Study coordinator: Michor, Franziska
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.